Randomized crossover clinical trial comparing the effects of alogliptin and linagliptin on glycemic metabolism in hemodialysis patients with type 2 diabetes mellitus

Randomized crossover clinical trial comparing the effects of alogliptin and linagliptin on glycemic metabolism in hemodialysis patients with type 2 diabetes mellitus - Comparison of alogliptin and linagliptin in hemodialysis patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010905

Enrollment

Registered

2013-06-10

Start date

2013-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients with type 2 diabetes mellitus

Interventions

Administration of alogliptin 6.25mg in the first 3 months followed by the administration of linagliptin 5mg for 3 months Administration of linagliptin 5mg in the first 3 months followed by the adminis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients of type 2 diabetes mellitus treated with DPP-4 inhibitors

Exclusion criteria

Exclusion criteria: 1)Patients who has a history of hypersensitivity 2)Pregnant or possibly pregnant women and women on lactation 3)Ineligible patients according to the investigator's judgment 4)The patients who do not agree with this study

Design outcomes

Primary

Measure	Time frame
glycoalbumin and Hemoglobin A1c	—

Secondary

Measure	Time frame
plasma glucose, C-peptide, LDL cholesterol, adverse event	—

Countries

Japan

Contacts

Public ContactYamashita Tetsuri

Minamisenju hospital Dialysis internal medicine

tetsuri218@yahoo.co.jp03-3806-2232

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026